1 Key Biotechnology Story for Indian Professionals

According to Press Monitor's print media monitoring and media intelligence tracking of Indian publications, this press review covers the most important news on biotechnology from today's media monitoring data. The shift toward non-animal drug testing through organ-on-chip technology marks a defining moment for India's pharmaceutical and biotech sectors.

1. India Adopts Chip-Based Drug Testing

A front-page report in Jansatta says India is advancing non-animal drug testing methods through organ-on-chip technology and computational models as alternatives to animal testing. The Central Drugs Standard Control Organisation is working to ban animal testing for cosmetics, and a two thousand twenty-three amendment to the New Drugs and Clinical Trials Rules has authorized human-cell-based testing, organ-chips, and microphysiological systems as non-clinical trial methods. Only five percent of animal-tested experiments receive human approval, highlighting the need for more relevant testing approaches.

Why it matters: India is advancing organ-on-chip technology and computational models as alternatives to animal testing, representing a major leap in biotechnology business innovation. This development reshapes how drugs are tested and approved across the country.

Key detail: Only five percent of animal-tested experiments receive human approval, underscoring the urgent need for more relevant, human-cell-based testing approaches. The Central Drugs Standard Control Organisation is actively working to ban animal testing for cosmetics, and a 2023 amendment to the New Drugs and Clinical Trials Rules has authorized human-cell-based testing, organ-chips, and microphysiological systems as non-clinical trial methods.

Source: Jansatta, Delhi, 15 September 2026

Next step: Stakeholders in pharma and biotech should prepare compliance frameworks aligned with the updated clinical trials rules and explore organ-on-chip partnerships.

Which regulatory change will accelerate adoption of chip-based drug testing in Indian biotechnology? Share your perspective with Press Monitor for the next press review.